Cyclophosphamide news

All news on Cyclophosphamide (also known as Cytoxan): plants, production capacities, investments and involved companies.

17 June 2026

Genentech seeks FDA approval for Lunsumio VELO plus Polivy in relapsed/refractory LBCL

sBLA accepted for subcutaneous bispecific + ADC combo in relapsed/refractory large B‑cell lymphoma; FDA decision expected Feb 9, 2027.

Who will be producing Cyclophosphamide in the future?

Find out with chemXplore Alpha

Learn more